• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

NICE 花了多长时间制定技术评估指南?一项回顾性研究,旨在估计指南制定时间的预测因素。

How long has NICE taken to produce Technology Appraisal guidance? A retrospective study to estimate predictors of time to guidance.

机构信息

London School of Hygiene and Tropical Medicine, London, UK.

出版信息

BMJ Open. 2013 Jan 11;3(1):e001870. doi: 10.1136/bmjopen-2012-001870.

DOI:10.1136/bmjopen-2012-001870
PMID:23315516
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3549260/
Abstract

OBJECTIVES

To assess how long the UK's National Institute for Health and Clinical Excellence's (NICE) Technology Appraisal Programme has taken to produce guidance and to determine independent predictors of time to guidance.

DESIGN

Retrospective time to event (survival) analysis.

SETTING

Technology Appraisal guidance produced by NICE. DATASOURCE: All appraisals referred to NICE by February 2010 were included, except those referred prior to 2001 and a number that were suspended.

OUTCOME MEASURE

Duration from the start of an appraisal (when the scope document was released) until publication of guidance.

RESULTS

Single Technology Appraisals (STAs) were published significantly faster than Multiple Technology Appraisals (MTAs) with median durations of 48.0 (IQR; 44.3-75.4) and 74.0 (IQR; 60.9-114.0) weeks, respectively (p <0.0001). Median time to publication exceeded published process timelines, even after adjusting for appeals. Results from the modelling suggest that STAs published guidance significantly faster than MTAs after adjusting for other covariates (by 36.2 weeks (95% CI -46.05 to -26.42 weeks)) and that appeals against provisional guidance significantly increased the time to publication (by 42.83 weeks (95% CI 35.50 to 50.17 weeks)). There was no evidence that STAs of cancer-related technologies took longer to complete compared with STAs of other technologies after adjusting for potentially confounding variables and only weak evidence suggesting that the time to produce guidance is increasing each year (by 1.40 weeks (95% CI -0.35 to 2.94 weeks)).

CONCLUSIONS

The results from this study suggest that the STA process has resulted in significantly faster guidance compared with the MTA process irrespective of the topic, but that these gains are lost if appeals are made against provisional guidance. While NICE processes continue to evolve over time, a trade-off might be that decisions take longer but at present there is no evidence of a significant increase in duration.

摘要

目的

评估英国国家卫生与临床优化研究所(NICE)技术评估计划产生指导的时间,并确定指导时间的独立预测因素。

设计

回顾性时间事件(生存)分析。

设置

NICE 发布的技术评估指南。

数据来源

除了 2001 年前提交和一些中止的评估外,所有在 2010 年 2 月前提交给 NICE 的评估都被包括在内。

结果测量

从评估开始(发布范围文件时)到发布指南的持续时间。

结果

单一技术评估(STA)的发布速度明显快于多技术评估(MTA),中位持续时间分别为 48.0(IQR;44.3-75.4)和 74.0(IQR;60.9-114.0)周(p<0.0001)。即使在调整了上诉因素后,中位发布时间也超过了公布的处理时间线。模型结果表明,在调整了其他协变量后,STA 发布指南的速度明显快于 MTA(快 36.2 周(95%CI-46.05 至-26.42 周)),对临时指南的上诉显著增加了发布时间(增加 42.83 周(95%CI 35.50 至 50.17 周))。在调整了潜在混杂变量后,没有证据表明癌症相关技术的 STA 比其他技术的 STA 完成时间更长,只有微弱的证据表明,每年制作指导的时间都在增加(增加 1.40 周(95%CI-0.35 至 2.94 周))。

结论

这项研究的结果表明,无论主题如何,STA 流程都导致了指导的显著加快,但如果对临时指导提出上诉,这些优势就会丧失。虽然 NICE 流程随着时间的推移继续发展,但权衡可能是决策需要更长的时间,但目前没有证据表明持续时间有显著增加。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ffe/3549260/30a31805ef98/bmjopen2012001870f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ffe/3549260/30a31805ef98/bmjopen2012001870f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ffe/3549260/30a31805ef98/bmjopen2012001870f01.jpg

相似文献

1
How long has NICE taken to produce Technology Appraisal guidance? A retrospective study to estimate predictors of time to guidance.NICE 花了多长时间制定技术评估指南?一项回顾性研究,旨在估计指南制定时间的预测因素。
BMJ Open. 2013 Jan 11;3(1):e001870. doi: 10.1136/bmjopen-2012-001870.
2
Single technology appraisals by NICE: are they delivering faster guidance to the NHS?英国国家卫生与临床优化研究所(NICE)的单一技术评估:它们是否在为英国国民医疗服务体系(NHS)更快地提供指导意见?
Pharmacoeconomics. 2008;26(12):1037-43. doi: 10.2165/0019053-200826120-00006.
3
NICE guidance: a comparative study of the introduction of the single technology appraisal process and comparison with guidance from Scottish Medicines Consortium.英国国家卫生与临床优化研究所指南:单一技术评估流程引入情况的比较研究以及与苏格兰药品联盟指南的对比
BMJ Open. 2012 Jan 30;2(1):e000671. doi: 10.1136/bmjopen-2011-000671. Print 2012.
4
The National Institute for Health and Clinical Excellence Single Technology Appraisal process: lessons from the first 4 years.国家卫生与临床优化研究所单一技术评估流程:头四年的经验教训。
Value Health. 2011 Dec;14(8):1158-65. doi: 10.1016/j.jval.2011.06.007. Epub 2011 Sep 8.
5
A Review of Issues Affecting the Efficiency of Decision Making in the NICE Single Technology Appraisal Process.关于影响英国国家卫生与临床优化研究所单一技术评估流程中决策效率的问题综述。
Pharmacoecon Open. 2019 Sep;3(3):403-410. doi: 10.1007/s41669-018-0113-0.
6
Does Methodological Guidance Produce Consistency? A Review of Methodological Consistency in Breast Cancer Utility Value Measurement in NICE Single Technology Appraisals.方法学指南能产生一致性吗?对英国国家卫生与临床优化研究所单一技术评估中乳腺癌效用值测量的方法学一致性的综述。
Pharmacoecon Open. 2018 Jun;2(2):97-107. doi: 10.1007/s41669-017-0040-5.
7
Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework.基于组织学的癌症药物建模方法,为 NICE 评估提供信息:系统评价和决策框架。
Health Technol Assess. 2021 Dec;25(76):1-228. doi: 10.3310/hta25760.
8
Appraisal of Novel Oncological Therapies by the Scottish Medicines Consortium and the National Institute for Health and Care Excellence: A Comparative Study of Six Years of Data.苏格兰药品联盟和英国国家卫生与临床优化研究所对新型肿瘤治疗方法的评估:六年数据的比较研究
Cureus. 2023 Dec 15;15(12):e50560. doi: 10.7759/cureus.50560. eCollection 2023 Dec.
9
Informing a decision framework for when NICE should recommend the use of health technologies only in the context of an appropriately designed programme of evidence development.为 NICE 何时应仅在适当设计的证据开发计划背景下推荐使用卫生技术制定决策框架提供信息。
Health Technol Assess. 2012;16(46):1-323. doi: 10.3310/hta16460.
10
An evaluation of the influence of the publication of the UK National Institute for health and Care Excellence's guidance on hypertension in pregnancy: a retrospective analysis of clinical practice.评估英国国家卫生与保健卓越研究所(NICE)发布的妊娠期高血压指南的影响:一项对临床实践的回顾性分析。
BMC Pregnancy Childbirth. 2020 Feb 12;20(1):101. doi: 10.1186/s12884-020-2780-y.

引用本文的文献

1
Barriers and facilitators to the implementation of guidelines in rare diseases: a systematic review.罕见病指南实施的障碍和促进因素:系统评价。
Orphanet J Rare Dis. 2023 Jun 7;18(1):140. doi: 10.1186/s13023-023-02667-9.
2
Health Technology Assessment of Drugs in Ireland: An Analysis of Timelines.爱尔兰药品的卫生技术评估:时间线分析
Pharmacoecon Open. 2020 Jun;4(2):287-296. doi: 10.1007/s41669-019-00177-8.
3
NICE and Fair? Health Technology Assessment Policy Under the UK's National Institute for Health and Care Excellence, 1999-2018.

本文引用的文献

1
NICE guidance: a comparative study of the introduction of the single technology appraisal process and comparison with guidance from Scottish Medicines Consortium.英国国家卫生与临床优化研究所指南:单一技术评估流程引入情况的比较研究以及与苏格兰药品联盟指南的对比
BMJ Open. 2012 Jan 30;2(1):e000671. doi: 10.1136/bmjopen-2011-000671. Print 2012.
2
Single technology appraisals by NICE: are they delivering faster guidance to the NHS?英国国家卫生与临床优化研究所(NICE)的单一技术评估:它们是否在为英国国民医疗服务体系(NHS)更快地提供指导意见?
Pharmacoeconomics. 2008;26(12):1037-43. doi: 10.2165/0019053-200826120-00006.
3
Does 'NICE blight' exist, and if so, why?
NICE 与公平?英国国家卫生与保健卓越研究所 1999-2018 年的卫生技术评估政策
Health Care Anal. 2020 Sep;28(3):193-227. doi: 10.1007/s10728-019-00381-x.
4
New Medicines in Wales: The All Wales Medicines Strategy Group (AWMSG) Appraisal Process and Outcomes.威尔士的新药:全威尔士药品策略组(AWMSG)评估程序与结果。
Pharmacoeconomics. 2018 May;36(5):613-624. doi: 10.1007/s40273-018-0632-7.
“英国国家卫生与临床优化研究所(NICE)弊病”存在吗?如果存在,原因是什么?
Pharmacoeconomics. 2008;26(12):987-9. doi: 10.2165/0019053-200826120-00002.
4
Comparing estimates of cost effectiveness submitted to the National Institute for Clinical Excellence (NICE) by different organisations: retrospective study.比较不同组织提交给英国国家卫生与临床优化研究所(NICE)的成本效益评估:回顾性研究。
BMJ. 2005 Jan 8;330(7482):65. doi: 10.1136/bmj.38285.482350.82. Epub 2004 Dec 15.